Abstract
The aim: of the study was to analyze the effectiveness of the adjuvant therapy for early chronic COVID-19 syndrome in patients with moderate or severe course who required hospital treatment.
Material and methods: at the outpatient visit of a pulmonologist to patients, after discharge from the hospital, in the presence of concomitant complaints from the respiratory system (shortness of breath, cough), cardiovascular system (tachycardia, increased blood pressure, arrhythmia), nervous system (emotional lability, disturbance of sleep, memory, attention) and general vegetative symptoms (weakness, asthenia), statin therapy (atorvastatin 20 mg or rosuvastatin 10 mg), ACE inhibitors (perindopril), with or without beta-blockers (depending on the pulse and blood pressure), ursodeoxycholic acid, ethylmethylhydroxypyridine succinate (Mexidol®) were added to the standard therapy with preventive doses of anticoagulants.
Results: We analyzed 70 treatment outcomes for 25-45 days with adjuvant therapy compared with 19 patients without it. At the time of initial admission, the cumulative intensity of these symptoms on a 10-point scale was 7.13 ± 0.34, in the comparison group – 7.01 ± 0.76, p>0.05. In the main group at the time of repeated admission the symptoms were noted with a severity of 4.43 ± 0.39 points, in the comparison group – 5.31 ± 0.48, p <0.05.
Conclusions: There was a statistically significant decrease in symptomatology in the group of patients with chronic COVID-19 syndrome, receiving the studied adjuvant therapy. This requires further research of these and other drugs in possible rehabilitation schemes for patients with moderate and severe Covid-19.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3674.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021